Article Date

How will the Pharma Industry respond to the unprecedented need for speed and scale to deliver vaccines for future pandemics?

The Pharma industry’s challenge to innovate vaccine manufacturing during the Pandemic was unprecedented. While the search for the vaccine progressed, the industry grappled with how to manufacture and deliver vaccines at the unprecedented scale and breakneck speed needed to supply the whole world. The challenge was met and many valuable lessons learned.

Attention is now focussing on how the Industry will more effectively respond to future pandemics. As industry expert, Austin Lock, PM Group writes in the ISPE’s iSpeak blog, “Even though multiple vaccines from a variety of different producers have been approved and delivered to nations across the world, many issues are still impacting production outputs. Which is why the industry must learn the many lessons from this experience—including those related to vaccine facility design and delivery and operation—in order to be able to respond much more effectively to future pandemics.” read more

Austin will be speaking at the ISPE Factory of the Future conference in September.

Masterplanning the future

Also speaking will be Jessica Hays, Project Manager, Strategic Projects, Bayer, and Jordaan Kemp, Director of Architecture, PM Group. Jessica and Jodaan will share their expert insights on site master planning the future and how it should adjust to accommodate new process modalities, delivery methods and Pharma 4.0™ technologies.


Register for the 2021 ISPE Facilities of the Future Conference to explore advancements in pharmaceutical technologies and see what pharmaceutical manufacturing facilities will look like in the future.


About Austin Lock

Austin is the technical director for the pharmaceutical sector of PM Group. He is a Chartered Chemical Engineer with Masters Degrees in both chemical engineering and pharmaceutical engineering. He has 30 years’ experience in the facility and process design of parenteral, biotech, vaccines, secondary, bulk sterile and bulk API facilities, working for a number of A/E and manufacturing companies. Austin has been with PM Group over 13 years working as a pharma SME, and is now leader of the pharma sector SME group and the Group's Technology Team (which focusses on technology innovation projects).